Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022
17. Juni 2022 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., June 17, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director,...
Altimmune to Participate at Two Upcoming Investor Conferences
03. Juni 2022 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., June 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...
Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
31. Mai 2022 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., May 31, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of...
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
20. Mai 2022 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at...
Altimmune to Present at Upcoming Investor Conferences
16. Mai 2022 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will...
Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update
12. Mai 2022 07:00 ET
|
Altimmune, Inc
GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31,...
Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12
05. Mai 2022 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., May 05, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2022 financial...
Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity
01. April 2022 07:00 ET
|
Altimmune, Inc
GAITHERSBURG, Md., April 01, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the 48-week...
Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
15. März 2022 07:01 ET
|
Altimmune, Inc
Data readouts from multiple clinical trials expected during the next 6 to 12 months Strong cash position of $190.3 million as of December 31, 2021 GAITHERSBURG, Md., March ...
Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
08. März 2022 07:00 ET
|
Altimmune, Inc
GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year...